From Regulation to Revelation: MDMA Therapy Through My FDA Lens
Last month while reading The New York Times, I came across an article that made me pause-not as a casual reader, but as someone who once stood inside the machinery of public health.
The topic? MDMA therapy-yes, the same compound once known to most of us as Ecstasy or Molly, now being used in carefully controlled settings to treat severe trauma.
And remarkably, this is not theoretical. It is already happening in Australia.
A Regulatory First-And a Bold One
In 2023, Australia became the first nation to formally allow psychiatrists to prescribe MDMA-assisted therapy for severe Post-Traumatic Stress Disorder.
From my years at the U.S. Food and Drug Administration, I can tell you: decisions like this are never taken lightly.
They require layers of evidence, debate, skepticism, and above all, responsibility to the public.
What Australia has done is bold, but not reckless.
It is the result of years of clinical trials suggesting that, under controlled conditions, MDMA can help patients revisit trauma without being overwhelmed by it.
The Science Meets the Human Condition
We in public health often speak in terms of data-percentages, outcomes, adverse effects.
But behind every dataset is a human story.
MDMA, as researchers describe it, reduces fear and increases emotional openness. It allows patients to confront memories they have spent years avoiding.
If traditional therapy is like knocking on a locked door, MDMA therapy may, at least for some -gently open it.
That, to me, is both fascinating and humbling.
The FDA Perspective: Why the U.S. Moves More Slowly
Here in the United States, the U.S. Food and Drug Administration has not yet approved MDMA therapy.
And I understand why. The FDA’s role is not to chase promise-it is to verify it.
Questions remain:
- Are the clinical trials sufficiently rigorous?
- Can results be replicated across diverse populations?
- What are the long-term safety implications?
- How do we prevent misuse outside controlled environments?
These are not bureaucratic hurdles. They are safeguards-hard-earned through decades of experience.
A Shift in How We View Healing
Yet, even with my regulatory instincts, I cannot ignore what this represents.
For decades, substances like MDMA were categorized solely as dangers placed firmly outside the boundaries of medicine.
Now, we are being asked to reconsider. Not recklessly. Not casually. But thoughtfully.
And perhaps that is the true story here-not just MDMA, but the evolution of medicine itself.
A Personal Reflection
Over the years through my time in public service, through witnessing national tragedies like 9/11, and through my daily discipline of writing since 2009, I have come to appreciate one simple truth:
Not all wounds are visible, and not all healing is straightforward.
We have long relied on conventional tools: medications, counseling, time.
But trauma has a way of resisting simplicity. Reading about MDMA therapy, I found myself thinking not as a regulator, but as a human being:
What if healing sometimes requires us to revisit the past, not with fear, but with compassion?
Hope, With Guardrails
Let me be clear-this is not a miracle cure. It is expensive. It is highly controlled. It is not suitable for everyone. And yes, it carries risks.
But it also carries something equally important: Possibility.
Closing Thoughts: The Balance Between Caution and Courage
If there is one lesson I carry from my FDA years, it is this:
Progress in medicine is always a balance between caution and courage.
Too much caution, and we delay relief for those who suffer. Too much courage, and we risk unintended harm. Australia has leaned forward.
The United States, through the U.S. Food and Drug Administration, remains measured.
Perhaps both approaches are necessary. As for me, I will continue to watch, to reflect, and as I have done since 2009, to write.
Because sometimes, the most important developments in life are the ones that challenge what we thought we already knew.
- FDA Rejection (August 2024): The FDA officially declined to approve MDMA capsules for PTSD treatment, as requested by Lykos Therapeutics, citing that the data submitted was not sufficient to show the treatment was safe and effective.
- Advisory Committee Vote: In June 2024, an FDA advisory panel voted 9-2 against the effectiveness of the treatment and 10-1 that the benefits did not outweigh the risks.
- Requirement for More Data: The FDA has asked for additional research, specifically requiring another randomized controlled trial to confirm the safety and efficacy of the drug.
- Blinding Issues: A major challenge is "unblinding." Because MDMA produces intense psychoactive effects, participants often know if they received the drug or a placebo, which can bias the results.
- Safety Data Limitations: The FDA noted risks such as increased heart rate and blood pressure (cardiovascular issues). Furthermore, they found the clinical laboratory data to be limited, and the potential for abuse was not adequately characterized.
- Therapy Standardization: The FDA noted that the psychotherapy component, which is inseparable from the drug treatment, was not sufficiently standardized, and the exact contribution of the psychotherapy to the positive outcomes was unclear.
- Functional Impairment: The FDA raised concerns regarding patient vulnerability during the session and the potential for abuse of the substance.
- Not the End of Research: While considered a major setback by advocates, the decision is viewed as a "reset" for the field to meet rigorous scientific standards rather than a permanent ban on psychedelic medicine.
- Ongoing Studies: Research continues, and the FDA has provided guidance on how to conduct studies to meet their regulatory requirements.
- Focus on Rigor: The FDA emphasizes that for approval, MDMA must meet the same stringent standards for data robustness as any other pharmaceutical drug.
- Meanwhile My Photos of the Day: Super Blooms in my Patio This Week
